At a holiday dinner, laughter and the aroma of home-cooked food fill the air, until someone says, “Did you hear about Uncle John? He’s been diagnosed with prostate cancer.” The table falls silent.
Why Genetic and Molecular Diagnostics Are the Next Frontier
Now imagine if the story ended differently: “OncoSure caught it before he even knew.” This time, smiles return. Hope abounds.
For too many families, cancer news arrives late, when treatment is more invasive, costly, and less likely to succeed. OncoSure is a pioneer in non-invasive diagnostics, revolutionizing cancer detection with a simple blood test that identifies cancer activity before symptoms appear. It delivers results within 24 hours and maintains 97.8 percent accuracy.
A One-Tube Revolution in Cancer Detection
With just a single tube of blood, OncoSure’s proprietary test detects oncosomes, microscopic messengers released by active cancer cells. These biomarkers are early indicators of cancer that are detectable before imaging methods like CT or PET scans show a tumor.
“For patients with no or low oncosomes, our test offers peace of mind. For those with high counts, it provides actionable information so their healthcare providers can take the next steps immediately,” explains Jason Andrews, VP.
This breakthrough combines proven science with proprietary innovation. OncoSure’s specialized probe binds to oncosomes and uses fluorescence in situ hybridization (FISH), a diagnostic method trusted for over 35 years, to precisely identify and count them. The test is radiation-free, non-invasive and far more affordable than using imaging. While CT scans, MRIs and PET scans typically cost between $3,000 and $7,000, OncoSure’s early detection test is priced at $895, with more and more insurers now offering coverage.
The process is straightforward. A single blood draw at any of OncoSure’s 2,400 partner locations gives patients and physicians a clear diagnostic picture within 24 hours. This accessibility and clinical accuracy position OncoSure as a game-changer in early cancer detection.
Our Ambition Is To Become A Household Name Within 3 To 5 Years. We Aim To Build A $25 Billion Company, But The Real Goal Is Saving Lives By Catching Cancer Before It Catches You
Why Genetic and Molecular Diagnostics Are the Next Frontier
While early cancer detection is its flagship focus, OncoSure offers a broader portfolio of genetic and molecular diagnostics that give patients and providers a comprehensive view of an individual’s health.
These include pharmacogenomics (PGx) testing, which helps doctors prescribe the right drug and dose based on a patient’s genetic profile. For preventive care, the Genetic Wellness Panel focuses on lifestyle-related health factors and common, manageable conditions. It assesses the predispositions to asthma, diabetes, obesity, allergies, and nicotine dependence, empowering individuals to make proactive lifestyle and healthcare choices before issues develop.
On the other hand, the Genetic Predisposition Panel is designed to identify inherited risks for serious, often life-threatening diseases. It evaluates genetic variants linked to cancers (such as breast, ovarian, prostate, and colorectal), cardiovascular disease, neurological disorders like Alzheimer’s and Parkinson’s, and autoimmune conditions. These insights support early medical monitoring, targeted prevention strategies, and long-term care planning.
OncoSure also offers advanced PCR diagnostic panels for highly accurate detection of infections, including UTIs, wound infections, STIs, HSV, respiratory illnesses, antibiotic resistance, and fungal infections.
By combining genomic science with clinical-grade accuracy, OncoSure enables proactive health strategies and personalized treatment plans, ensuring care guided by each patient’s DNA for better outcomes.
A Game-Changing Approach to Monitoring and Cost Savings
-
For Patients With No Or Low Oncosomes, Our Test Offers Peace Of Mind. For Those With High Counts, It Provides Actionable Information So Their Healthcare Providers Can Take The Next Steps Immediately
A Game-Changing Approach to Monitoring and Cost Savings
OncoSure’s test doesn’t just identify cancer early—it also enables real-time monitoring during treatment. If a patient begins treatment with an oncosome count of 400 and it doesn’t drop to 250–275 after 40 days, it’s a clear sign the therapy isn’t working. This approach is a game-changer, allowing doctors to adjust treatments sooner instead of waiting 12 weeks for expensive and physically exhausting chemotherapy cycles, ultimately saving time and money.
By detecting cancer early, the cost of treatment can be reduced by as much as 20 times. Treating advanced cancer costs between $1 million and $1.5 million per patient, whereas early detection and intervention cost only $20,000 to $50,000 per year.
A Vision Born from Innovation
OncoSure Testing began with a bold idea and the determination to change how the world approaches cancer. It started with Dr. Ramesh Babu, a lead diagnostic scientist at Quest Diagnostics, who discovered a way to detect the earliest signs of cancer activity—before a tumor even forms. His proprietary DNA probe, capable of binding to oncosomes (microscopic signals shed by active cancer cells), promised to rewrite the rules of early detection.
When Quest declined to pursue his innovation, Dr. Babu refused to let the idea die. He left to launch IntergenCdx, dedicating himself to bringing his life saving technology to patients.
Five years ago, Jason Andrews and his partners recognized the breakthrough potential of Dr. Babu’s work. They acquired the probes, then poured resources into research, development, and clinical trials. Two and a half years ago, their persistence paid off: OncoSure secured CPT codes for insurance reimbursement, completed clinical validation, and officially launched, transforming a visionary concept into a national solution for proactive cancer detection.
From Reactive to Proactive Healthcare
OncoSure’s ultimate goal is to shift healthcare from a reactive model to a proactive one. Andrews envisions a future where cancer detection is not reserved for those already showing symptoms.
“Imagine if we could test children as young as 10 to establish their baseline oncosome levels. Throughout their lives, we’d monitor for any sudden changes, catching cancer before it has a chance to develop. This approach could save millions of lives and billions of healthcare dollars,” says Andrews. To spread awareness, OncoSure has launched grassroots outreach initiatives, social media campaigns, and partnerships with organizations like the Beat Cancer Foundation, which has 19,000 members, many of whom are cancer survivors. The collaboration ensures regular monitoring of individuals in remission, significantly reducing the risk of recurrence.
The Experts behind the Science
Behind OncoSure’s success is a team of highly skilled laboratory specialists and scientists. Dr. Phoutthasone Thirakul, Laboratory Director, leads the team, who is double board-certified in Anatomic, Clinical, and Forensic Pathology. She brings unmatched expertise in diagnostic precision, quality control, and regulatory compliance.
Jahmar Hudson, chief scientific officer and a leading molecular diagnostics expert, supports her. Hudson oversees assay development, molecular science innovations, and technical operations while mentoring the next generation of laboratory professionals. Stephanie Altidort, General Supervisor of Molecular Pathology, ensures that every high-complexity test adheres to the highest CLIA standards for quality assurance and staff competency.
Stephanie Lucce, a skilled Molecular Technologist, and William Wysock, a veteran Molecular Scientist with over two decades of experience and Six Sigma certification, add further depth. Their expertise in PCR, next-generation sequencing, and assay validation ensures that every OncoSure test is clinically actionable, precise, and reliable.
Scaling a Mission to Improve Patient Outcomes
OncoSure is on a hypergrowth trajectory. The company has already doubled its laboratory capacity across the U.S and is in active discussions with CMS to roll out a pilot program that could redefine cancer screening in the country. By scaling up to 300,000–400,000 tests per month, OncoSure plans to reduce the price of its test to around $495, making it even more accessible without compromising profitability.
“Our ambition is to become a household name within 3 to 5 years. We aim to build a $25 billion company, but the real goal is saving lives by catching cancer before it catches you,” says Andrews.
With cancer rates rising and the disease now the leading cause of death in the U.S., the need for innovation has never been greater. OncoSure Testing’s mission is not just about diagnostics but hope, prevention, and giving people control over their health. Combining cutting-edge science, affordability, and accessibility, OncoSure is poised to transform cancer care for generations.
Phone Number:1888 925 4816
Website: oncosuretesting.com
What Defines a Gold Standard in Early Cancer Detection Testing
Cancer screening decisions increasingly sit at the intersection of clinical urgency, payer scrutiny and patient access. For executives evaluating early cancer detection testing providers, speed and technological novelty alone are no longer sufficient differentiators. The more important question is whether a test can provide clinically actionable direction before symptoms emerge, invasive diagnostics become necessary, or late-stage imaging begins to dictate the care pathway. In life science technology, a key indicator for value is the timeliness of the signal detection, its specificity of guidance to the next clinical step and its adaptability to diverse populations without increased cost or work.
One disadvantage of many of the screening tests now available is the limited coverage they provide. Tests directed only at germline risk, restricted cancer panels or those that identify detectable lesions on imaging are useful, but leave a great void in cases where activity exists outside predetermined parameters or has not yet reached structural consequence. Better models are seeking signs of active biologic processes, not past predisposition or present physical state that is just arriving. For employers, payers, networks of providers and health systems, the difference counts because there is no value to early detection unless you can tell passive risk from active clinical worry. Buyers should focus on test strategies that help them make appropriate clinical decisions rather than creating general probabilistic anxiety with no immediate guidance. The best platforms reduce ambiguity by giving clinicians some indication of whether they need further investigation and how quickly it should occur.
Accessibility is similarly important. Tools requiring high-cost imaging systems, challenging logistical arrangements, or multiple rounds of radiation exposure may not serve as scalable solutions for the population level. The providers who are successful reduce workflow requirements through simple data collection, rapid turnaround time and easy-to-interpret reports for the physician. Financial visibility is also key, as many screening programs fail when patients, payers, or physicians are unable to project cost. A well-behaved early detection partner should allow for a manageable screening process while still offering the necessary clinical information for safe decision-making for follow-up. Broad adoption depends on integrating smoothly into existing healthcare workflows, reimbursement structures and patient engagement pathways without turning preventive oncology into a specialist-limited service.
Executives should also evaluate value beyond a single screening event. Effective cancer management requires earlier signals, but it also benefits from tools capable of monitoring whether treatment is producing meaningful change and whether recurrence may be developing after remission. With tests which not only produce a quantitative baseline but also monitor the biological effect over time, the treating clinician and payer body will have a much more manageable means by which to stratify risk, response and monitor progress. The best providers integrate science, patient ease and economic efficiency rather than having organizations compromise clinical accuracy for wider access.
Within this landscape, OncoSure Testing presents a particularly strong option. The company focuses on detecting oncosomes, cancer-associated extracellular vesicles released by active cancer cells, through a blood-based testing process using rapid in situ hybridization and DNA fluorescent probe technology. Its model supports simple blood collection, broad cancer screening applications, oncosome quantification, rapid reporting, and treatment-monitoring use cases. The company’s all-inclusive pricing approach, nationwide site accessibility and ongoing engagement with payers and CMS strengthen its position for organizations seeking early detection solutions that are scalable rather than merely technologically novel. Executives looking for an accessible, clinically directive, evidence-based method of cancer screening should consider OncoSure Testing.
...Read more
Early Cancer Detection Testing Info
Q1
What distinguishes OncoSure Testing among Top Early Cancer Detection Testing Companies?
OncoSure Testing has earned recognition among Top Early Cancer Detection Testing Companies through its specialized focus on blood-based biomarker testing designed to identify cancer risk at earlier stages. The company’s flagship ONCOSure™ test measures the ENOX2 biomarker, which has been associated with multiple cancer types before symptoms become clinically apparent. Its approach emphasizes non-invasive screening methods that support earlier intervention opportunities and broader accessibility compared to more invasive diagnostic procedures. OncoSure Testing also differentiates itself through its long-standing research in cancer biomarker science and its commitment to preventive oncology applications.
Q2
How does OncoSure Testing approach early cancer detection?
Biomarker-driven analysis forms the foundation of the company’s testing strategy. Unlike some Early Cancer Detection Testing Companies that rely heavily on imaging or highly invasive procedures, OncoSure Testing focuses on blood-based molecular detection methods designed to identify cancer-associated protein activity. The ONCOSure™ platform analyzes circulating ENOX2 protein variants linked to different cancer types and tissue origins, helping physicians evaluate cancer presence earlier in the disease process. Its testing model also supports ongoing patient monitoring and risk assessment through minimally invasive blood collection methods.
Q3
Why is OncoSure Testing relevant to modern cancer screening efforts?
Healthcare systems continue to prioritize earlier diagnosis because cancer detection at earlier stages is often associated with improved treatment options and patient outcomes. OncoSure Testing addresses this growing healthcare need through Early Cancer Detection Testing Companies solutions designed to support proactive cancer screening and preventive oncology strategies. Its blood-based testing platform aligns with increasing demand for less invasive diagnostic technologies capable of improving screening accessibility and patient participation. The company’s work also reflects broader industry interest in liquid biopsy technologies and molecular diagnostics for earlier disease identification.
Q4
What role does scientific innovation play at OncoSure Testing?
Research-driven biomarker development remains central to OncoSure Testing’s scientific identity. The company’s technology originated from extensive studies involving ENOX2 protein expression and its association with malignant cellular activity. Its testing platform applies molecular biology and protein biomarker analysis to improve cancer detection capabilities across multiple cancer categories. Early Cancer Detection Testing Companies often differentiate themselves through biomarker specificity and clinical relevance, and OncoSure Testing reinforces that distinction through its focus on non-invasive molecular diagnostics and ongoing cancer biomarker research.
Q5
How does OncoSure Testing support healthcare professionals and patients?
Accessible screening support plays an important role in the company’s service model. OncoSure Testing provides healthcare professionals with blood-based diagnostic information designed to complement broader clinical evaluation and patient monitoring strategies. Its testing approach supports physicians seeking additional molecular insights when assessing cancer risk or monitoring treatment progress. Among Early Cancer Detection Testing Companies, the company distinguishes itself through its emphasis on simplified screening accessibility and patient-friendly testing methods designed to encourage earlier evaluation and ongoing surveillance.
Q6
Why has OncoSure Testing gained visibility in cancer diagnostics discussions?
Industry attention toward liquid biopsy technologies and preventive oncology has strengthened visibility for organizations advancing non-invasive cancer detection methods. OncoSure Testing continues to build recognition through its work involving ENOX2 biomarker analysis and blood-based cancer screening applications. Its emphasis on earlier molecular detection reflects broader healthcare interest in diagnostic tools capable of identifying cancer before traditional clinical symptoms emerge. This combination of biomarker expertise, non-invasive testing and preventive screening focus reinforces OncoSure Testing’s standing among Early Cancer Detection Testing Companies.
